Aswanth Reddy

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

UA Fort Smith

Faculty Researcher

2 h-index 31 pubs 42 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Aswanth Reddy's research focuses on the application of immunotherapies and targeted treatments for various cancers. His work includes reviews and case studies on bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, particularly in the context of lung cancer and colorectal cancer. Reddy has investigated the response of EGFR-mutated non-small cell lung cancer to pembrolizumab and the successful treatment of HER2-mutated colorectal cancer with fam-trastuzumab deruxtecan. Additionally, his research extends to understanding cardiovascular events related to anti-androgen therapy and the impact of germline genetic mutations in breast cancer patients. He has collaborated extensively with colleagues at the University of Arkansas – Fort Smith, including Maha Zafar and Nkolika Nwankwo.

Metrics

h-index: 2
Publications: 31
Citations: 42

Selected Publications

Abstract PS5-04-16: Analysis of Efficacy, Safety and Cost of Datopotamab Deruxtecan and Sacituzumab Govitecan for Advanced Hormone Positive Breast Cancer Patients (2026)

Clinical Cancer Research DOI OpenAlex
Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102) (2026)

JNCI Journal of the National Cancer Institute 4 citations DOI OpenAlex
Mortality trends of chronic lymphocytic leukemia and pneumonia in the United States (1999–2023): A CDC-wonder analysis (2025)

Blood DOI OpenAlex
Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status (2025)

Blood DOI OpenAlex
Rising mortality trends in elderly multiple myeloma patients with hypertension: A CDC wonder database analysis (1999–2023) (2025)

Blood DOI OpenAlex
Comparative efficacy of complement inhibitors in complement Inhibitor–Naïve PNH: A network meta-analysis of randomized trials (2025)

Blood DOI OpenAlex
AML-463: Unraveling a Unique Presentation of Cold Agglutinin Disease in Myeloid Malignancy (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
A Rare Finding of Secondary Spontanous Pneumothorax (SSP) During Tyrosine Kinase Inhibitor Treatment of a Patient With Metastatic Synovial Sarcoma (2025)

American Journal of Respiratory and Critical Care Medicine 1 citation DOI OpenAlex
Treatment of Aggressive B Cell Lymphoma with Epcoritamab - Real World Single Institution Experience (2024)

Blood DOI OpenAlex
EP.11A.22 Comparing Outcomes and Adverse Events in Lung Cancer Immunotherapy: The Impact of Smoking Status (2024)

Journal of Thoracic Oncology 1 citation DOI OpenAlex
MM-361 Central Nervous System Relapse of Multiple Myeloma: A Case Report (2024)

Clinical Lymphoma Myeloma & Leukemia 1 citation DOI OpenAlex